Trial Profile
A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and ribavirin therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms ATTAIN
- Sponsors Janssen R&D Ireland; Tibotec Inc
- 31 Jul 2021 This trial has been completed in Spain, according to the European Clinical Trials Database record.
- 10 Oct 2014 Additional data in European and Israeli patients were presented at the Viral Hepatitis Congress (VHC).
- 12 May 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.